Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 182 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eosinophilic Gastroenteritis Clear all
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
Biological · Other
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis

NCT05482256
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Esophageal String Test (EST), Colgate, High Resolution Esophageal Manometry (HREM)
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

NCT00635089
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
reslizumab
Drug
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

NCT02379052
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Image the Esophagus Using the OFDI Capsule

NCT02204150
View directory record Official record
Conditions
Barrett's Esophagus, Eosinophilic Esophagitis
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Pilot Study of Esocheck in Eosinophilic Esophagitis

NCT04311970
View directory record Official record
Conditions
Eosinophilic Esophagitis, Diagnoses Disease
Interventions
EsoCheck
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

NCT04856891
View directory record Official record
Conditions
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids

NCT02610816
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs)
Interventions
1 Food Elimination Diet, 4 Food Elimination Diet, 4 Food Elimination Diet (post 1FED failure), Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
Other · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Active, not recruiting No phase listed Observational

Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population

NCT05176249
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 21 Years
Enrollment
300 participants
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Placebo, lirentelimab (AK002)
Other · Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children

NCT03342391
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Transnasal esophagoscopy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 22 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

NCT00638456
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide plus Prevacid, placebo plus Prevacid
Drug
Lead sponsor
Ranjan Dohil
Other
Eligibility
1 Year and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Not applicable Interventional

EoE Food Desensitization

NCT02881372
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral food desensitization
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model

NCT01040598
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Omalizumab
Biological
Lead sponsor
O & O Alpan LLC
Other
Eligibility
12 Years to 76 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Springfield, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

NCT02736409
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (OBS), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)

NCT03191864
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo
Drug
Lead sponsor
Adare Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Chandler, Arizona • Tucson, Arizona • Sherwood, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Mucosal Impedance and Eosinophilic Esophagitis

NCT01953575
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Mucosal Impedance, Upper Endoscopy
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

NCT03029091
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 25 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
La Jolla, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Validation Phase)

NCT04941742
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Effectiveness of Biofeedback-Assisted Relaxation Training in Children With Eosinophilic Duodenitis

NCT00124501
View directory record Official record
Conditions
Abdominal Pain, Duodenitis
Interventions
Biofeedback-assisted relaxation training
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

NCT00880906
View directory record Official record
Conditions
Suspected Eosinophilic Esophagitis
Interventions
Esophageal dilation, Steroid and Proton Pump Inhibitor Therapy
Procedure · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

NCT02897271
View directory record Official record
Conditions
Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Denver, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 17, 2026, 4:09 AM EDT